logo
Share SHARE
FONT-SIZE Plus   Neg

AVEO Reports Publication Of Positive Tivozanib Phase 2 Results - Quick Facts

AVEO Pharmaceuticals Inc. (AVEO) said the previously reported results from a Phase 2 trial evaluating the efficacy and safety of tivozanib in 272 patients with advanced renal cell carcinoma were published in the Journal of Clinical Oncology. Results showed improved median progression-free survival or PFS among patients treated with tivozanib compared with placebo, and that tivozanib was well tolerated with minimal off-target toxicities, the company added.

Phase 2 trial's positive results informed the design and implementation of TIVO-1, a pivotal Phase 3 study in advanced RCC demonstrating tivozanib superiority over sorafenib in the primary endpoint of PFS in the first-line setting, top-line data from which were reported in January 2012.

Based on the positive Phase 2 data and success of the TIVO-1 trial, AVEO and its collaborator Astellas Pharma Inc. are moving forward with plans for submitting the tivozanib NDA in RCC in the third quarter of 2012, with the MAA submission to follow.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota is working on developing an electric car with a fast charging battery, the Chunichi Shimbun reported on Tuesday. Travelers leaving Comic-Con International in San Diego last weekend were in for a rude shock after United Airlines said that comic books were banned in their checked luggage. United Airlines claimed it was a Transportation Security Administration or TSA-mandated rule for all airlines operating out of San Diego over this weekend. A Singapore-based startup wants to make cryptocurrencies like Bitcoin go mainstream and be available for everyday transactions. TenX has built an app that serves as a digital wallet connected to the Visa card. The debit card will instantly convert multiple digital currencies into fiat money such as the dollars, yen and euros.
comments powered by Disqus
Follow RTT